Evidence map›Paper›PMID 41818153›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets.

Qiaoyu Hu, Yu Cao, PengXuan Ren, Xianglei Zhang, Fenglei Li, Xueyuan Zhang, Fengyu Cai, Ran Zhang, Yongqi Zhou, Lianghe Mei and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qiaoyu Hu *Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.ORCID 0009-0003-9834-5153
Yu Cao *Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
PengXuan Ren *Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Xianglei ZhangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Fenglei LiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Xueyuan ZhangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Fengyu CaiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Ran ZhangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Yongqi ZhouShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Lianghe MeiSuzhou Institute of Materia Medica, Chinese Academy of Sciences, Suzhou 215004, China.ORCID 0000-0001-9874-0397
Fang BaiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0003-1468-5568

Funding

Fundamental Research Program of Shanxi Province 202503021212159MOST | National Key Research and Development Program of China (NKPs) 2022YFC3400501 2022YFC3400500Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Foundation) 24JS2850200 25DX2800400ShanghaiTech AI4S Initiative SHTAI4S202404
6 · The paper itself

Abstract

Targeted protein degradation is a promising strategy for drug discovery, but designing effective PROTACs remains challenging, especially for proteins without well-defined binding sites. Current methods rely on modifying linkers between fixed ligands, which limits the diversity and innovation of the overall molecular architecture of PROTAC. Here, we introduce DeepDegradome, an AI-powered method that automates the structure-aware design of both small-molecule ligands and PROTACs. It employs a large fragment library constructed from public databases and applies an in-house docking method (iFitDock) to obtain initial binding fragments. DeepDegradome builds ligands by assembling these fragments based on the shape and physicochemical features of the target protein pocket. It can further construct PROTACs from these generated ligands, eliminating the dependency on predefined warheads or E3 ligands. Compared to other AI models, DeepDegradome produces more valid, drug-like molecules with higher predicted binding affinity. We demonstrate DeepDegradome's effectiveness by designing and validating multiple potency inhibitors and PROTACs for two protein targets: WDR5 and CDK9. One synthesized compound showed excellent agreement between predicted and actual binding conformation confirmed by X-ray crystallography. By combining ligand and PROTAC design in one system, DeepDegradome offers a scalable and reliable tool for discovering new drugs against protein targets.

Indexed as

Deep LearningDrug DiscoveryProteinsBinding SitesDrug DesignHumansLigandsMolecular Docking SimulationProtein BindingProteolysisProteolysis Targeting ChimeraSmall Molecule LibrariesLigandsProteinsProteolysis Targeting ChimeraSmall Molecule Librariesdeep learningfragment-based drug designmolecular generationPROTACs

Identifiers

PMID41818153
PMCPMC12994176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.